OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- Inova Health Care Services
- Study ID
- NCT06939751
- Status
- Recruiting
Conditions
- Cardiac Failure
- Graft Rejection
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 99 Years
- Healthy Volunteers
- Not accepted
Study Details
This study aims to develop and refine a microRNA (miR) biomarker panel that can be used to phenotype net immune state after heart transplantation using circulating miRs (associated with drug doses and levels). These miRs will be used to characterize the overall immune state in adult heart transplant patients and predict patients that will go on to develop infection and rejection. MicroRNAs (miRs) are small, non-coding RNA molecules that regulate gene expression and serve as molecular biomarkers found in the circulation.
Key Dates
- Start date
- Oct 28, 2025
- Status verified
- Apr 2026
- Primary completion
- Jan 1, 2031
- Completion
- Jan 1, 2032
Study Design
- Enrollment
- 250 participants (estimated)
Primary Outcome Measure
Time-to-Event Analysis of Circulating microRNAs (miRs) Predicting Infection in Pediatric Heart Transplant Recipients [ Time Frame: up to 3 years post - transplant ]
Central Contacts
- Palak Shah, MD(703) 776-8000
- Stephanie Wolak, MPH571-472-8558
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | Lucilla Garcia Jon Kobashigawa, MD (PRINCIPAL_INVESTIGATOR) |
| Stanford University | Palo Alto | California | 94304 | James Pak Kiran Khush, MD (PRINCIPAL_INVESTIGATOR) |
| Tufts Medical Center | Boston | Massachusetts | 02111 | Jeong Hwan Kim, MD (PRINCIPAL_INVESTIGATOR) |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | Melissa Amitrano Ryan Tedford, MD (PRINCIPAL_INVESTIGATOR) |
| Vanderbilt University | Nashville | Tennessee | 37232 | Lisa Slinger Kelly Schlendorf, MD (PRINCIPAL_INVESTIGATOR) |
| Baylor University Medical Center | Dallas | Texas | 75246 | Jasha Harvey Shelley Hall, MD (PRINCIPAL_INVESTIGATOR) |
| Inova Health System | Falls Church | Virginia | 22042 |
Find similar trials in Los Angeles, CA
Related Studies
- Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney TransplantationPHASE2 · Enrolling By Invitation · The Methodist Hospital Research Institute · Houston, Texas
- Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAsRecruiting · Inova Health Care Services · Aurora, Colorado
- Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell TransplantsRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland
- A Preliminary Study for INFORMEDPHASE4 · Enrolling By Invitation · Weill Medical College of Cornell University · New York, New York